3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
6
Neoplasms
5
Small Cell Lung Carcinoma
3
Neoplasm Metastasis
3
Nasopharyngeal Carcinoma
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Advanced Cancer
2
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Stereotactic Body Radiation Therapy
1
Sarcoma
1
Recurrence
1
Platinum-resistant Recurrent Clear Cell Ovarian Cancer
1
Pheochromocytoma
1
Paraganglioma, Extra-Adrenal
1
Paraganglioma
1
Pancreatic Neoplasms
1
NSCLC
1
Lung Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Colonic Neoplasms
1
Carcinoma, Medullary
1
Brain Neoplasms
1
Advanced Solid Tumors
1
Advanced Malignancy
1
Advanced Endometrial Cancer
1
Adenocarcinoma of Lung
1
Interventions
Carboplatin
41
Paclitaxel
32
Radiotherapy
28
Cisplatin
25
Bevacizumab
24
Erlotinib Hydrochloride
19
Pemetrexed
18
Docetaxel
16
Gemcitabine
15
Gefitinib
8
Vinorelbine
7
Taxes
7
Cetuximab
7
ceritinib
5
Surgical Procedures, Operative
5
Etoposide
5
Amplified Fragment Length Polymorphism Analysis
5
sargramostim
3
pembrolizumab
3
capmatinib
3
Radiotherapy, Conformal
3
Radiation
3
Gene Expression Profiling
3
Cyclophosphamide
3
2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a
3
trametinib
2
pegfilgrastim
2
osimertinib
2
Topotecan
2
Tirapazamine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Adenocarcinoma of Lung
×
anlotinib
×
Clear all
NCT04770688
2024-08-15
AUTOMAN
Shanghai Chest Hospital
Phase 1/2
Completed
25 enrolled